腹膜透析清除尿毒症溶质。
The Removal of Uremic Solutes by Peritoneal Dialysis.
机构信息
Departments of Medicine, Stanford University and VA Palo Alto HCS, Palo Alto, California.
Division of Nephrology and Department of Medicine, University Health Network and the University of Toronto, Canada.
出版信息
J Am Soc Nephrol. 2023 Dec 1;34(12):1919-1927. doi: 10.1681/ASN.0000000000000211. Epub 2023 Aug 9.
Peritoneal dialysis (PD) is now commonly prescribed to achieve target clearances for urea or creatinine. The International Society for Peritoneal Dialysis has proposed however that such targets should no longer be imposed. The Society's new guidelines suggest rather that the PD prescription should be adjusted to achieve well-being in individual patients. The relaxation of treatment targets could allow increased use of PD. Measurement of solute levels in patients receiving dialysis individualized to relieve uremic symptoms could also help us identify the solutes responsible for those symptoms and then devise new means to limit their accumulation. This possibility has prompted us to review the extent to which different uremic solutes are removed by PD.
目前，腹膜透析（PD）常用于达到尿素或肌酐的目标清除率。然而，国际腹膜透析学会（ISPD）提出，不应再强加此类目标。该学会的新指南建议，PD 处方应进行调整，以实现个体患者的健康。治疗目标的放宽可能会增加 PD 的使用。对接受透析的患者进行溶质水平的个体化测量，以缓解尿毒症症状，也有助于我们确定导致这些症状的溶质，并随后设计新的方法来限制其积累。这一可能性促使我们回顾 PD 去除不同尿毒症溶质的程度。
Zotero 插件